Surprise Billing: Arbitration Will Raise Your Premiums
As we continue our national discussion of how to address surprise billing, one idea that keeps coming up – and needs to stop – is arbitration.
Insys Therapeutics Admits to Bribing Doctors to Write Opioid Prescriptions
Imagine for a second that you knew a product you were manufacturing was killing people in droves. Now think about being the type of company who would bribe a doctor to prescribe that product to their patients. It’s inconceivable. It’s reprehensible. It’s exactly what Insys Therapeutics was doing.
SB 432 – Lots of Treats for Pharmacists – and Bad News for Consumers
Anti-Pharmacy Benefit Manager (PBM) legislation has been pushed by big pharma this year, and for an obvious reason – their bottom line. HB 534, the “Pharmacy Benefits Manager Licensure Act” would have massively hampered the ability for your insurer’s PBM to negotiate the price of drugs. This would have resulted in higher costs of medication, which in turn would mean higher health insurance premiums. It was the kind of bill that would have hit North Carolina’s families and businesses - already struggling with rising health care costs - hard.
Podcast: Senator Joyce Krawiec Talks to Us About Why CON Laws are Bad for NC
When asked who might be against the removal of outdated and restrictive Certificate of Need (CON) laws, Senator Joyce Krawiec lets out a laugh. It’s not a nervous laugh, but one that’s hearty and genuine. More than anything, it’s a gesture of astonishment and bewilderment. So, just who would be against ridding the state of guidelines that limit new healthcare providers from entering the market?
Study Finds Prescription Drugs Double in Price Every 7 to 8 Years
It’s an obvious exaggeration to say that drug prices will have increased again by the time you finish reading this sentence, but it’s probably not that far off. A new study published in the Journal of the American Medical Association (JAMA) Network Open says that the cost of brand-name prescription drugs doubled every 7 to 8 years.
Federal Judge’s Ruling Deals Blow to Quest for Drug Price Transparency
In yet another clear sign of Big Pharma’s desire to deceive consumers, three of the world’s largest drugmakers sued—and won—to halt a rule that would require more transparency in drug pricing. The rule would have compelled pharma companies to prominently include the wholesale cost of their drugs on any television advertising, but a federal judge earlier this month struck it down.